Concepts (127)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin Neoplasms | 8 | 2019 | 403 | 2.170 |
Why?
|
| Melanoma | 6 | 2019 | 332 | 1.650 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2018 | 705 | 0.850 |
Why?
|
| Hidradenitis Suppurativa | 1 | 2022 | 11 | 0.720 |
Why?
|
| Acne Vulgaris | 1 | 2022 | 23 | 0.720 |
Why?
|
| Dermatologists | 2 | 2018 | 11 | 0.720 |
Why?
|
| Dielectric Spectroscopy | 2 | 2019 | 3 | 0.610 |
Why?
|
| Sunscreening Agents | 5 | 2019 | 22 | 0.610 |
Why?
|
| Self-Examination | 1 | 2018 | 5 | 0.570 |
Why?
|
| Sunburn | 1 | 2018 | 13 | 0.570 |
Why?
|
| Electric Impedance | 1 | 2018 | 37 | 0.550 |
Why?
|
| Margins of Excision | 1 | 2018 | 31 | 0.540 |
Why?
|
| Mohs Surgery | 1 | 2018 | 53 | 0.530 |
Why?
|
| Decision Support Techniques | 1 | 2018 | 193 | 0.480 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2018 | 260 | 0.460 |
Why?
|
| Gene Expression Profiling | 2 | 2018 | 793 | 0.450 |
Why?
|
| Paget Disease, Extramammary | 1 | 2012 | 3 | 0.380 |
Why?
|
| Scrotum | 1 | 2012 | 8 | 0.380 |
Why?
|
| Chordoma | 1 | 2012 | 5 | 0.370 |
Why?
|
| Exanthema | 1 | 2012 | 25 | 0.370 |
Why?
|
| Sacrum | 1 | 2012 | 24 | 0.370 |
Why?
|
| Bone Neoplasms | 1 | 2012 | 121 | 0.340 |
Why?
|
| Skin | 3 | 2022 | 415 | 0.240 |
Why?
|
| Humans | 19 | 2023 | 64913 | 0.220 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 1104 | 0.220 |
Why?
|
| Agammaglobulinemia | 1 | 2023 | 9 | 0.200 |
Why?
|
| Genetic Diseases, X-Linked | 1 | 2023 | 10 | 0.200 |
Why?
|
| Dermatologic Agents | 1 | 2022 | 21 | 0.180 |
Why?
|
| Sebaceous Glands | 1 | 2022 | 6 | 0.180 |
Why?
|
| Masks | 1 | 2021 | 20 | 0.180 |
Why?
|
| Psoriasis | 1 | 2022 | 60 | 0.180 |
Why?
|
| Hair Follicle | 1 | 2022 | 35 | 0.180 |
Why?
|
| Sun Protection Factor | 2 | 2019 | 2 | 0.180 |
Why?
|
| Biological Products | 1 | 2022 | 92 | 0.170 |
Why?
|
| Surveys and Questionnaires | 2 | 2018 | 2759 | 0.160 |
Why?
|
| Antirheumatic Agents | 1 | 2022 | 227 | 0.150 |
Why?
|
| United States | 5 | 2018 | 8067 | 0.150 |
Why?
|
| Skin Aging | 1 | 2019 | 11 | 0.150 |
Why?
|
| Marketing | 1 | 2019 | 21 | 0.150 |
Why?
|
| Consumer Behavior | 1 | 2019 | 38 | 0.150 |
Why?
|
| Patient Medication Knowledge | 1 | 2018 | 3 | 0.150 |
Why?
|
| Dermatologic Surgical Procedures | 1 | 2019 | 35 | 0.140 |
Why?
|
| Drug Labeling | 1 | 2018 | 23 | 0.140 |
Why?
|
| Aged | 7 | 2018 | 14872 | 0.140 |
Why?
|
| Epidemiologic Methods | 1 | 2018 | 67 | 0.140 |
Why?
|
| Physician Assistants | 1 | 2018 | 40 | 0.140 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2019 | 48 | 0.140 |
Why?
|
| Frozen Sections | 1 | 2018 | 10 | 0.140 |
Why?
|
| False Negative Reactions | 1 | 2018 | 41 | 0.140 |
Why?
|
| False Positive Reactions | 1 | 2018 | 77 | 0.140 |
Why?
|
| Dermatology | 1 | 2018 | 66 | 0.130 |
Why?
|
| Nurse Practitioners | 1 | 2018 | 120 | 0.130 |
Why?
|
| Health Personnel | 1 | 2021 | 385 | 0.130 |
Why?
|
| Neoplasm Metastasis | 1 | 2018 | 221 | 0.130 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 168 | 0.130 |
Why?
|
| Drug Compounding | 1 | 2018 | 79 | 0.130 |
Why?
|
| Quality Improvement | 1 | 2021 | 458 | 0.130 |
Why?
|
| Regional Health Planning | 1 | 2016 | 10 | 0.130 |
Why?
|
| Hospital Charges | 1 | 2016 | 22 | 0.130 |
Why?
|
| Patient Care Bundles | 1 | 2016 | 11 | 0.130 |
Why?
|
| Diabetic Angiopathies | 1 | 2016 | 29 | 0.130 |
Why?
|
| Safety-net Providers | 1 | 2016 | 31 | 0.120 |
Why?
|
| Disease Management | 1 | 2018 | 233 | 0.120 |
Why?
|
| Hospital Costs | 1 | 2016 | 127 | 0.120 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 1160 | 0.110 |
Why?
|
| Female | 7 | 2018 | 33857 | 0.110 |
Why?
|
| Male | 6 | 2018 | 30898 | 0.100 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 1690 | 0.100 |
Why?
|
| Adolescent | 2 | 2022 | 6305 | 0.100 |
Why?
|
| Benzenesulfonates | 1 | 2012 | 13 | 0.090 |
Why?
|
| Niacinamide | 1 | 2012 | 32 | 0.090 |
Why?
|
| Phenylurea Compounds | 1 | 2012 | 31 | 0.090 |
Why?
|
| Education, Medical, Continuing | 1 | 2012 | 92 | 0.090 |
Why?
|
| Pyridines | 1 | 2012 | 116 | 0.090 |
Why?
|
| Frontotemporal Lobar Degeneration | 1 | 2011 | 20 | 0.080 |
Why?
|
| Awareness | 1 | 2011 | 73 | 0.080 |
Why?
|
| Self Concept | 1 | 2011 | 118 | 0.080 |
Why?
|
| Cognition Disorders | 1 | 2011 | 223 | 0.070 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2019 | 39 | 0.070 |
Why?
|
| Time Factors | 4 | 2018 | 3757 | 0.070 |
Why?
|
| Middle Aged | 4 | 2018 | 18169 | 0.070 |
Why?
|
| Antineoplastic Agents | 1 | 2012 | 642 | 0.060 |
Why?
|
| Adult | 3 | 2018 | 17284 | 0.060 |
Why?
|
| Cross-Sectional Studies | 3 | 2018 | 2697 | 0.060 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2011 | 515 | 0.060 |
Why?
|
| Prognosis | 2 | 2019 | 1775 | 0.050 |
Why?
|
| Biological Factors | 1 | 2022 | 19 | 0.050 |
Why?
|
| Insurance Claim Review | 1 | 2022 | 75 | 0.050 |
Why?
|
| Ipilimumab | 1 | 2019 | 8 | 0.040 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 1 | 2019 | 6 | 0.040 |
Why?
|
| Protective Factors | 1 | 2019 | 33 | 0.040 |
Why?
|
| Coffee | 1 | 2019 | 18 | 0.040 |
Why?
|
| United States Food and Drug Administration | 1 | 2018 | 90 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2019 | 246 | 0.030 |
Why?
|
| Secondary Prevention | 1 | 2019 | 164 | 0.030 |
Why?
|
| Baths | 1 | 2018 | 7 | 0.030 |
Why?
|
| Aerosols | 1 | 2018 | 46 | 0.030 |
Why?
|
| Primary Prevention | 1 | 2019 | 136 | 0.030 |
Why?
|
| Terminology as Topic | 1 | 2018 | 145 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2018 | 141 | 0.030 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2019 | 202 | 0.030 |
Why?
|
| Biopsy | 1 | 2019 | 454 | 0.030 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2019 | 111 | 0.030 |
Why?
|
| Texas | 1 | 2016 | 59 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2019 | 249 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2019 | 491 | 0.030 |
Why?
|
| Drug Utilization | 1 | 2018 | 204 | 0.030 |
Why?
|
| Fee-for-Service Plans | 1 | 2016 | 71 | 0.030 |
Why?
|
| Water | 1 | 2018 | 313 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2018 | 740 | 0.030 |
Why?
|
| Genomics | 1 | 2019 | 384 | 0.030 |
Why?
|
| Early Detection of Cancer | 1 | 2019 | 325 | 0.030 |
Why?
|
| Transcriptome | 1 | 2018 | 396 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 734 | 0.030 |
Why?
|
| Healthcare Disparities | 1 | 2016 | 408 | 0.020 |
Why?
|
| Agnosia | 1 | 2011 | 3 | 0.020 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2011 | 23 | 0.020 |
Why?
|
| Temporal Lobe | 1 | 2011 | 46 | 0.020 |
Why?
|
| Problem Solving | 1 | 2011 | 31 | 0.020 |
Why?
|
| Frontal Lobe | 1 | 2011 | 63 | 0.020 |
Why?
|
| Exercise | 1 | 2018 | 960 | 0.020 |
Why?
|
| Reference Values | 1 | 2011 | 328 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2022 | 6831 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2011 | 409 | 0.020 |
Why?
|
| Risk Factors | 1 | 2019 | 5407 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2011 | 1135 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2016 | 5774 | 0.010 |
Why?
|